EnClear Therapies was conceived by the founders of QurAlis and Q-State Bio, with the sole purpose of developing novel device-based therapies to treat patients with neurodegenerative disease. The companies first products will aim to halt the progression of ALS and PSP.
At EnClear Therapies, leading scientific and clinical minds in the field of neurodegenerative disease have come together with experts in medical device design to bring new therapies to patients who currently have no other options for treatment.
The EnClear Team
Scientific Advisory Board
Kevin Eggan, Ph.D.
Professor of Stem Cell and Regenerative Biology at Harvard University
Clifford Woolf, Ph.D.
Director FM Kirby Neurobiology Center at Children's Hospital Boston
Manuel Navia, Ph.D.
Founder & President, Hub-Bio Strategic Advising
Bernhardt Trout, Ph.D.
Raymond F. Baddour, ScD, (1949) Professor of Chemical Engineering, MIT and Member of the Advisory Board at Hedgeness
Clinical Advisory Board
William Brian Gormley, MD, MPH, MBA
Director. Neurosurgical Critical Care, BWH
Assistant Professor of Surgery. Harvard Medical School
Josh Vose, MD, MBA
Medical Director, Medical and Clinical Affairs Professional, Physician and Engineer
Board Of Directors
Jonathan Fleming, M.P.A.
President & CEO Q-State Bio
Anthony R. DePasqua
President & CEO EnClear Therapies
Kasper Roet, Ph.D.
Principal, Amgen Ventures at Amgen